Welcome to the FDA Recalls and Warnings Update, a series dedicated to keeping you informed about the latest medication recalls, manufacturing violations, and quality concerns affecting your prescriptions. In this installment, we’re highlighting three recalls for compounded semaglutide and tirzepatide and one recall for the GLP-1 brand-name drug Wegovy (tirzepatide). Semaglutide is the active ingredient in Ozempic (for type 2 diabetes) and Wegovy (for weight loss). Tirzepatide is the active ingredient in Mounjaro (for type 2 diabetes) and Zepbound (for weight loss).
This installment also features two FDA warning letters directed at GLP-1 compounding pharmacies because of violations at their manufacturing facilities.
What You Need to Know About Compounding Pharmacies
The pharmacies in the Drug Recalls section of this installment are “503A compounding pharmacies.” They are licensed by state boards of pharmacies but are not subject to FDA inspections or “current good manufacturing practice” (cGMP) standards. Instead, they must follow U.S. Pharmacopeia (USP) compounding quality standards. 503A pharmacies prepare custom prescriptions tailored to the needs of individual patients.
The pharmacies in the Facility Inspections Warning Letters section are FDA-registered “503B outsourcing facilities.” They operate under stricter oversight, must follow “current good manufacturing process” (CGMP), and use ingredients sourced from FDA-registered suppliers. These pharmacies are allowed to make large batches of drugs for distribution to healthcare facilities.
Pharmacies making or distributing compounded GLP-1s use active pharmaceutical ingredients (APIs) that often are not evaluated or inspected by the FDA. Many of these API manufacturers are based overseas.
Due to rising reports of fraudulent, tainted, or unsafe shipments of semaglutide and tirzepatide entering the U.S., the FDA has created a ‘green list’ of API manufacturers whose facilities meet its safety standards. APIs not on that list may be detained at the border under new import alert rules.
All of the recalls in this installment have been assigned a “Class II” level by the FDA (see below for definitions of types of recalls).
How to Read This Report
This report is prepared using the most recent information posted in the FDA’s Enforcement Reports Database (for recalls), Warning Letters Database (for warning letters), and Drug Imports Alerts Database (for drug importers subject to import bans). Not all new entries to the databases are included in this report. Selected entries are chosen based on the type of product and the potential safety impact of the recall or warning.
Recall announcements and warnings are simplified to improve clarity and accessibility. In some cases, additional sources such as company statements, FDA press releases, and industry publications may provide further details. The primary sources for this report include:
Recalls (Enforcement Reports Database)
The Food and Drug Administration (FDA) categorizes product recalls in its Enforcement Report database based on the level of health risk, labeling them as Class I, II, III, or “not yet classified.”
While the database includes drugs, food, cosmetics, medical devices, biologics, tobacco, and veterinary products, this report only covers selected drug recalls.
- Class I recalls are the most serious. In these situations, there is “reasonable probability that the use of or exposure to a product will cause serious adverse health consequences or death.”
- Class II recalls are for drugs that may cause temporary or medically reversible adverse health consequences or where use of the product is unlikely to result in serious adverse health consequences.
- Class III recalls are the least serious. Use of the product is not likely to cause adverse health consequences.
Warning Letters (Warning Letters Database)
Drug manufacturers, supplement companies, and medical device makers may receive a Warning Letter from the FDA if they commit serious violations of federal regulations. This letter comes from an overseeing FDA office, such as the Center for Drug Evaluation and Research. Common violations include poor manufacturing practices, false product claims, selling misbranded items, or marketing unapproved products. The letter gives the recipient a chance to correct the issues and requires a response, usually within 15 days.
Drug Imports Alerts Database
FDA Import Alerts notify field staff and the public when the agency has enough evidence to detain products without physical examination (DWPE) due to suspected violations of FDA laws, including violations of “current good manufacturing practices for finished pharmaceuticals” or unapproved new drugs. The violations lists are arranged by type of violation, then by country and then by the importing company. In some cases, Import Alerts may be linked to Warning Letters for issues like manufacturing violations.
Drug Recalls
Semaglutide/Cyanocobalamin and Tirzepatide/Niacinamide
Company: Aequita Pharmacy (licensed compounding pharmacy)
Location: Kirkland, Washington
Scope: Over 2,000 multi-dose vials of injectable GLP-1 semaglutide/cyanocobalamin and tirzepatide/niacinamide combination products not yet expired. Strengths of the recalled semaglutide products range from .22 mg to 2.67 mg. Strengths of the recalled tirzepatide products range from 2.2 mg to 16.6 mg.
Drug Description: Treats type 2 diabetes and obesity; these formulations contain added vitamins
Recall Reason: A lack of processing controls. Lack of oversight in the compounding facility could impact medication sterility, dosage accuracy, and stability.
Essential Extras: Cyanocobalamin (Vitamin B12) and niacinamide (Vitamin B3) are sometimes added by compounding pharmacies to semaglutide or tirzepatide formulations. Some claim these vitamins help reduce side effects. Just as importantly, the addition of extra ingredients creates a formulation that differs from the branded products, which compounders may use as a legal justification to avoid producing an outright copy of a brand-name drug.
Recall Initiation Date: July 18, 2025
Link: FDA Enforcement Report
Semaglutide
Company: Boothwyn Pharmacy, LLC (licensed compounding pharmacy)
Location: Kennett Square, Pennsylvania
Scope: Semaglutide, 2.5 mg/mL injection: .8 mL (186 vials), 2 mL (642 vials), 4 mL (648 vials)
Drug Description: Treats type 2 diabetes and obesity
Recall Reason: Subpotent drugs (which means they less than the specified amount of active ingredient)
Recall Initiation Date: July 9, 2025
Link: FDA Enforcement Report
Semaglutide, Semaglutide/Cyanocobalamin, Tirzepatide, Tirzepatide/Cyanocobalamin
Company: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)
Location: Englewood, Colorado
Scope: Semaglutide: 5 mg/mL (164 pre-filled syringes); Semaglutide/Cyanocobalamin: 5mg/1mg/mL, (28 pre-filled syringes); Tirzepatide/Cyanocobalamin: 15mg/0.5mg/0.5mL (242 pre-filled syringes), 15mg/1mg/mL (216 pre-filled syringes); Tirzepatide: 20mg/mL (826 pre-filled syringes); smaller quantities of other concentrations also recalled.
Drug Description: Treats type 2 diabetes and obesity; these formulations contain added vitamins
Recall Reason: Lack of assurance of sterility
Essential Extras: Thrive Health Solutions is a “whole body health clinic” (or medical spa), focused on weight loss and aesthetics. In a statement regarding the availability of compounded semaglutide and tirzepatide products, Thrive says it uses “FDA-licensed compounding pharmacy partners.” Cyanocobalamin (Vitamin B12) and niacinamide (Vitamin B3) are sometimes added by compounding pharmacies to semaglutide or tirzepatide formulations. Some claim these vitamins help reduce side effects. Just as importantly, the addition of extra ingredients creates a formulation that differs from the branded products, which compounders may use as a legal justification to avoid producing an outright copy of a brand-name drug.
Recall Initiation Date: May 21, 2025
Link: FDA Enforcement Report
Wegovy (semaglutide)
Company: Cardinal Health (drug distributor)
Company Location: Dublin, Ohio
Manufacturing Location: Novo Nordisk, Bagsvaerd, Denmark
Scope: 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton (48 cartons)
Drug Description: Weight loss treatment
Recall Reason: Product was not stored under labeled storage temperature requirements due to a shipping error involving a Cardinal Health distribution center. The product was removed from refrigerated storage for an extended period of time.
Recall Initiation Date: April 9, 2025
Link: FDA Enforcement Report
Facility Inspections – FDA Warning Letters
ProRx, LLC
Type: Compounding pharmacy and FDA-registered outsourcing facility
FDA Department issuing Warning: Center for Drug Evaluation and Research (CDER)
Warning Letter Date: January 15, 2025
Facility Location: Exton, Pennsylvania
Date(s) of Inspections: July 15, 2024, to August 2, 2024; Inspection report (Form FDA 483) sent August 2, 2024
FDA Warning: Drug products failed to meet the requirements of approved outsourcing facilities under Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act): Current good manufacturing practice (CGMP) violations resulted in adulterated drug products. Inspectors found compounded drug products used bulk drug substance from a source that is not an FDA-registered establishment. Product labels did not include the required information. Procedures for reporting adverse events were inadequate. Products intended or expected to be sterile were prepared, packed, or held under unsanitary conditions.
Types of Products Made: Compounded pharmaceutical products including vancomycin, semaglutide and tirzepatide.
Essential Extras: More than 15,000 vials of ProRx’s compounded semaglutide and tirzepatide products were recalled in August 2024 due to a lack of assurance of sterility.
Link: FDA Warning Letter
Read the warning letter for a complete description of violations.
Company: Tailstorm Health Inc., doing business as Medivant Health
Type: Compounding pharmacy and FDA-registered outsourcing facility
Warning Letter Date: April 8, 2025
FDA Department issuing Warning: Center for Drug Evaluation and Research (CDER)
Facility Location: Phoenix, Arizona
Inspection Dates: September 24, 2024, to October 10, 2024; Inspection report (Form FDA 483) sent October 10, 2024
FDA Warning: Drug products failed to meet the requirements of approved outsourcing facilities under Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Drug products, such as Semaglutide Injection and Tirzepatide Injection, did not include necessary statements on the labels. Violations of current good manufacturing practice (CGMP) resulted in adulterated products. Products intended or expected to be sterile were prepared, packed, or held under unsanitary conditions.
Essential Extras: Tailstorm initiated a voluntary recall of the drug bevacizumab in November 2024 due to concerns over sterility.
Types of Products Made: Pre-filled sterile injectable products and repackaged products, including single-dose liquid injectable vials
Link: FDA Warning Letter
Read the warning letter for a complete description of violations.
